Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

Port of Auckland to pay $45m special dividend to council
Finance

Port of Auckland to pay $45m special dividend to council

The divestment proceeds will be used to top up the Auckland Future Fund.

Oliver Lewis 27 Jun 2025
$600m in tourist spend at risk from regulation: Mastercard
Finance

$600m in tourist spend at risk from regulation: Mastercard

When Europe cut interchange fees, foreign card decline rates soared.

Pattrick Smellie 27 Jun 2025
Michael Lorimer exits Grant Samuel amid more sector change
Finance

Michael Lorimer exits Grant Samuel amid more sector change

Lorimer has sold his 80% stake in the corporate advisory firm.

Duncan Bridgeman 26 Jun 2025